【通化东宝利拉鲁肽注射液获哥伦比亚GMP证书】 近日,通化东宝与合作伙伴科兴生物制药股份有限公司携手的出海产品—利拉鲁肽注射液,正式获得哥伦比亚国家食品药品监督管理局颁发的GMP证书,为后续该产品在哥伦比亚的获批上市,以及拉美其他国家的市场准入打下坚实基础。利拉鲁肽注射液作为GLP-1受体激动剂,凭借其降糖、减重及心血管保护的多重疗效,已成为全球糖尿病治疗的一线药物,受到患者的广泛认可。

金融界
17 Apr
近日,通化东宝与合作伙伴科兴生物制药股份有限公司携手的出海产品—利拉鲁肽注射液,正式获得哥伦比亚国家食品药品监督管理局颁发的GMP证书,为后续该产品在哥伦比亚的获批上市,以及拉美其他国家的市场准入打下坚实基础。利拉鲁肽注射液作为GLP-1受体激动剂,凭借其降糖、减重及心血管保护的多重疗效,已成为全球糖尿病治疗的一线药物,受到患者的广泛认可。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10